{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-26-022428","form_type":"8-K","ticker":"BIAF","cik":"0001712762","company_name":"bioAffinity Technologies, Inc.","filed_at":"2026-05-12T13:20:15+00:00","discovered_at":"2026-05-12T13:21:00.304903+00:00","generated_at":"2026-05-12T13:21:15.154532+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"medium","headline":"bioAffinity CyPath Lung unit sales nearly 300% higher in April 2026 vs 2025","bullets":["Record monthly CyPath Lung unit sales in April 2026; preliminary data shows ~300% YoY increase over April 2025.","Sales growth so far in 2026 exceeds internal projections, reflecting accelerating physician adoption.","CyPath Lung uses flow cytometry + AI for noninvasive lung cancer detection; 92% sensitivity, 87% specificity in trial.","Company advancing longitudinal clinical study, expanding use for lung cancer survivor monitoring, and R&D pipeline for asthma/COPD.","CEO Maria Zannes highlights CyPath Lung's role in risk stratification and nodule management."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-26-022428","json":"https://secwatch.observer/filing/0001493152-26-022428.json","markdown":"https://secwatch.observer/filing/0001493152-26-022428.md","text":"https://secwatch.observer/filing/0001493152-26-022428.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1712762/000149315226022428/0001493152-26-022428-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1712762/000149315226022428/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-12T13:21:15.154532+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}